<DOC>
	<DOCNO>NCT00368030</DOCNO>
	<brief_summary>The purpose study evaluate subjective sleep efficacy subject insomnia related major depressive disorder .</brief_summary>
	<brief_title>A Study Eszopiclone Subjects With Insomnia Related Major Depressive Disorder</brief_title>
	<detailed_description>This study double-blind , randomize , placebo-controlled , parallel group study . The study consist two group subject major depression treat ten week common antidepressant regimen , 20-40 mg fluoxetine hydrochloride per day ; randomize receive ( addition ) either eszopiclone 3 mg placebo eight week . This study previously post Sepracor Inc . In October 2009 , Sepracor Inc. acquire Dainippon Sumitomo Pharma. , October 2010 , Sepracor Inc 's name change Sunovion Pharmaceuticals Inc .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Eszopiclone</mesh_term>
	<criteria>Subject must understand purpose study willing adhere study schedule procedure describe protocol . Subject must 21 64 year age ( inclusive ) day sign consent . Subject must meet criterion primary principal diagnosis Major Depressive Disorder . Subject 's current depressive episode least 2 week longer 6 month duration . Subject must meet criterion insomnia relate MDD symptom insomnia must predate symptom MDD 10 week . Subject must report sleep onset time &gt; 30 minute , wake time sleep onset &gt; 45 minute , &lt; 6.5 hour total sleep time least three time week previous month . Subject must take HamiltonD17 scale protocol prespecified minimum score . Subject must know clinically significant abnormal laboratory , ECG , physical examination finding screen . Subject must meet one follow condition : Subject take antidepressant medication time study start . Subject take subtherapeutic dose antidepressant disallow psychotropic medication approval investigator agree taper medication , prior completion screen assessment study start . Female subject pregnant , lactate within 6 month post partum . Subject know sensitivity selective SSRI , zopiclone , eszopiclone . Subject history major depressive disorder refractory treatment SSRIs . Subject current primary psychiatric diagnosis follow disorder : dementia , delirium , schizophrenia , psychosis , psychotic disorder , dysthymic disorder ; bipolar disorder ; cyclothymic disorder , mood disorder , nocturnal panic disorder , primary anxiety disorder , primary panic disorder psychiatric disorder would compromise investigator 's ability evaluate safety efficacy study medication . Note : Subjects Sexual Gender Identity Disorders nonpsychotic disorder consider casebycase basis . Subjects MDD secondary diagnosis generalize anxiety disorder , panic disorder nocturnal panic disorder seasonal affective disorder allow . Subject follow Personality Disorders diagnose : schizotypal , schizoid , borderline personality disorder ; mental retardation personality disorder would compromise investigator 's ability evaluate safety efficacy study medication . Subject difficulty sleep initiation maintenance associate know medical diagnosis [ e.g . sleep apnea , restless leg syndrome ( RLS ) , periodic leg movement syndrome ( PLMS ) ] , condition may affect sleep [ ( e.g. , chronic pain , benign prostatic hypertrophy ( BPH ) ] . Subject clinically significant unstable medical neurologic abnormality , unstable chronic disease , history clinically significant abnormality cardiovascular , respiratory , hepatic , renal system . Subject disorder history condition ( e.g. , malabsorption , gastrointestinal surgery ) may interfere drug absorption , distribution , metabolism , excretion . Subject history malignancy within 5 year , current malignancy , except nonmelanoma skin cancer . Subject history drug alcohol abuse dependence past 6 month positive urine drug alcohol test screening . Subject participating , participate , plan participate investigational drug study within 30 day prior screen end study . Subject history circadian rhythm disorder , travel across &gt; 3 time zone regular basis . Subject know seropositive Human Immunodeficiency Virus ( HIV ) . Subject used drug know suspected affect hepatic renal clearance capacity within period 30 day prior screen . Subject unwilling refrain drink alcoholic beverage study participation . Subject rotate third/night shift worker . Subject staff member relative staff member .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Insomnia relate major depressive disorder .</keyword>
</DOC>